Opthea To Present at H.C. Wainwright 2nd Annual Ophthalmology Virtual Conference
Dr Megan Baldwin, the Company’s Chief Executive Officer, will present at H.C. Wainwright 2nd Annual Ophthalmology Virtual Conference August 17.
WebcastOpthea To Present at H.C. Wainwright Annual Global Life Sciences Conference
Dr Megan Baldwin, the Company’s Chief Executive Officer, will present at H.C. Wainwright Annual Global Life Sciences Conference May 23-25.
WebcastOpthea To Present at Citi Biopharma Virtual Co-Panel day
Dr Megan Baldwin, the Company’s Chief Executive Officer, will present on the Citi Biopharma virtual Co-Panel day Ophthalmology Panel on May 18, 2022
WebcastARVO 2022 Annual Meeting
Opthea Presented Efficacy and Safety of OPT-302 in combination with Ranibizumab for Polypoidal Choroidal Vasculopathy at ARVO 2022
Poster PresentationASX Small – Mid Cap Conference 2022
Opthea Presented at the ASX Small – Mid Cap Conference 2022
Angiogenesis 2022 – Prof Cheung presentation of PCV data
OPT-302 Combination Therapy in Polypoidal Choroidal Vasculopathy.
Download PDF
Opthea Corporate Presentation August 2022
MST Access Initiation of Coverage report: In its ‘Lines’ of Sight
Opthea Meets Primary Endpoint in Phase 2b Study of OPT-302 – Company Conference Call
Opthea Presentation on Phase 2b Data for the EURETINA Congress
6 September 2019
6 September 2019
Beyond anti-VEGF-A for Retinal Diseases
6 November 2018 in New York
6 November 2018 in New York
MST Access Initiation of Coverage report: In its ‘Lines’ of Sight
Opthea Meets Primary Endpoint in Phase 2b Study of OPT-302 – Company Conference Call
Opthea Presentation on Phase 2b Data for the EURETINA Congress
6 September 2019
6 September 2019
Beyond anti-VEGF-A for Retinal Diseases
6 November 2018 in New York
6 November 2018 in New York